Formulation and biopharmaceutical evaluation of a transdermal patch containing letrozole

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 2-3, 2010, Pages 138-149

  Li, Li ^a,b   Fang, Liang ^a   Xu, Xinlan ^a   Liu, Yu ^a,b   Sun, Yinghua ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b LIAONING UNIVERSITY   (China)

Author keywords

In vitro; In vivo; Letrozole; Pharmacokinetic; Transdermal patch

Indexed keywords

ADHESIVE AGENT; CARBAMAZEPINE; LAUROCAPRAM; LETROZOLE; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG PENETRATION; FEMALE; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; NONHUMAN; RAT; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; FEMALE; HUMANS; MALE; MICE; MICE, HAIRLESS; NITRILES; RATS; RATS, WISTAR; SKIN; SKIN ABSORPTION; TRIAZOLES;

EID: 77951035245     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.698     Document Type: Article

References (32)

1. Ranade VV. Drug delivery systems 6. Transdermal drug delivery. J Clin Pharmacol 1991; 31: 401-418.
2. Modamio P, Lastra CF, Marino EL. A comparative in vitro study of percutaneous penetration of beta-blockers in human skin. Int J Pharm 2000; 194: 249-259. (Pubitemid 30110687)
3. Adrian PF, Roman S, Hans WM, Clemens G, Rainer HM, Ralph L. Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations. Pharm Res 2002; 19: 661-668.
4. Ke GM,Wang L, Xue HY, et al. In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children. Biol Pharm Bull 2005; 28: 305-310.
5. Piccart J. The changing landscape of breast cancer clinical research. Ann Oncol 1998; 9: 133-138.
6. Takashi S, Yasuhiro M, Noriaki O, Hironobu S. Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer 2008; 15: 270-277.
7. Chen S, Masri S, Wang X, Phung S, Yuan YC, Wu XW.What do we know about the mechanisms of aromatase inhibitor resistance. J Steroid Biochem Mol Biol 2006; 102: 232-240. (Pubitemid 44750638)
8. Labrie F, Luu TV, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepian-drosterone. Endocr Rev 2003; 24: 152-182. (Pubitemid 36515283)
9. Suzuki T, Miki Y, Nakamura Y, et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 2005; 12: 701-720. (Pubitemid 41815772)
10. Tan HS, Pfister WR. Pressure-sensitive adhesives for transdermal drug delivery systems. Pharm Sci Technol Today 1999; 2: 60-69. (Pubitemid 29130314)
11. Zhao LG, Fang L, Xu YN, Liu S, He ZG, Zhao YY. Transdermal delivery of penetrants with differing lipophilicities using O-acylmenthol derivatives as penetration enhancers. Eur J Pharm Biopharm 2008; 69: 199-213.
12. Zhao LG, Fang L, Xu YN, Zhao YY, He ZG. Effect of O-acylmenthol on transdermal delivery of drugs with different lipophilicity. Int J Pharm 2008; 352: 92-103. (Pubitemid 351273923)
13. Pang KS, Lee WF, Cherry WF, et al. Effects of perfusate flow rate on measured blood volume, disse space, intracellular water space, and drug extraction in the perfused rat liver preparation: characterization by the multiple indicator dilution technique. J Pharmacokinet Biopharm 1988; 16: 595-632.
14. St-Pierre MV, Schwab AJ, Goresky CA, Lee WF, Pang KS. The multiple-indicator dilution technique for characterization of normal and retrograde flow in once-through rat liver perfusions. Hepatology 1989; 9: 285-296.
15. Valiverti S, Hammell DC, Paudel IS, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evaluation of 3-alkyl ester transdermal prodrugs of naletrozolerexone in hairless guinea pigs. J Control Release 2005; 102: 509-520.
16. Bian SJ, Doh HJ, Zheng JM, Kim JS, Lee CH, Kim DD. In vitro evaluation of patch formulations for topical delivery of gentistic acid in rats. Eur J Pharm Sci 2003; 18: 141-147.
17. Cho YJ, Choi HK. Enhancement of percutaneous absorption of ketoprofen: effect of vehicles and adhesive matrix. Int J Pharm 1998; 169: 95-104.
18. Kim JH, Cho YJ, Choi HK. Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin. Int J Pharm 2000; 196: 105-113.
19. Stoughton R. Enhanced percutaneous penetration with 1- dodecylazacycloheptan-2-one. Arch Dermatol 1982; 118: 474-477.
20. Adachi Y, Hosaya K, Sugibayashi K, Morimoto Y. Duration and reversibility of the penetration-enhancing effect of N-dodecylazepan-2-one. Chem Pharm Bull 1988; 36: 3702-3705.
21. Wiechers J, Drenth B, Jonkman J, De Zeeuw R. Percutaneous absorption, metabolism and elimination of the penetration enhancer N-dodecylazepan-2-one in humans after prolonged application under occlusion. Int J Pharm 1988; 47: 43-49.
22. Chatterjee DJ, Li WY, Koda RT. Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Pharm Res 1997; 14: 1058-1065.
23. Joseph AN, Timothy MM, Barry LR, Barrie CF. Synergistic enhancement of testosterone transdermal delivery. J Control Release 2005; 103: 577-585.
24. Diez-Sales O, Watkinson AC, Herraez-Dombinguez M, Javaloyes C, Hadgraft J. A mechanistic investigation of the in vitro human skin permeation enhancing effect of Azone. Int J Pharm 1996; 129: 33-40.
25. Vaddi HK, Ho PC, Chan SY. Terpenes in propylene glycol as skin penetration enhancers: permeation and partition of haloperidol, Fourier transform infrared spectroscopy, and differential scanning calorimetry. J Pharm Sci 2002; 91: 1639-1651.
26. Kang L, Ho PC, Chan SY. Interactions between a skin penetration enhancer and the main components of human stratum corneum lipids. Isothermal titration calorimetry study. J Therm Anal Calorim 2006; 83: 27-30.
27. Nakamura Y, Takayama K, Higashiyama K, Suzuki T, Nagai T. Promoting effect of O-ethylmenthol on the percutaneous absorption of ketoprofen. Int J Pharm 1996; 145: 29-36.
28. Obata Y, Li CJ, Fujikawa M, et al. Evaluation and structure-activity relationship of synthesized cyclohexanol derivatives on percutaneous absorption of ketoprofen using artificial neural network. Int J Pharm 2001; 212: 223-231.
29. Takanashi Y, Higashiyama K, Komiya H, Takayama K, Nagai T. Thiomenthol derivatives as novel percutaneous absorption enhancers. Drug Dev Ind Pharm 1999; 25: 89-94.
30. Barry BW. Mode of action of penetration enhancers in human skin. J Control Release 1987; 6: 85-97.
31. Goodman M, Barry BW. Lipid-protein-partitioning (LPP) theory of skin enhancer activity: finite dose technique. Int J Pharm 1989; 57: 29-40.
32. Roy SD, Gutierrez M, Flynn GL, Cleary GW. Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. J Pharm Sci 1996; 85: 491-495.